With the rapid advancement of rapid PCR amplification technology, there has been explosive growth in the field of molecular diagnostics for infectious diseases, particularly with a focus on decentralized laboratory testing and point-of-care (POC) devices. Nucleic acid-based tests (NATs) are often considered the gold standard for infectious disease diagnostics, and a paradigm shift has occurred with a new focus on the performance of rapid, simple NATs at, or near, the site of patient care.
 
 

For respiratory viral panel PCR, specifically, the MUR-24, a comprehensive 24-in-1 molecular point-of-care test, stands out. This test panel, designed for twenty-four upper respiratory pathogens, leverages the power of rapid PCR amplification technology to deliver fast and accurate results. The MUR-24 is a game-changer in respiratory viral panel testing, providing healthcare professionals with the ability to perform a broad range of diagnostic tests at the point of care, significantly reducing the turnaround time for results and minimizing the risk of infections spreading within healthcare facilities. The Hysen MUR-24 respiratory viral panel includes the Novel Coronavirus, Influenza A Virus, Influenza A/H1, Influenza A H1N1 pdm09 Virus, Influenza A/H3, Influenza A/H5, Influenza B Virus, Parainfluenza virus type I/II/III/IV, Respiratory syncytial virus A/B, Human metapneumovirus, Rhinovirus, Bocavirus, Adenovirus, Enterovirus, Coronavirus 229E, Coronavirus OC43, Coronavirus NL63, Coronavirus HKU1, Bordetella pertussis, Bordetella parapertussis, Bordetella holmesii, Mycoplasma pneumoniae, and Chlamydia pneumoniae.

Hysen MUR-24 respiratory viral panel